Biovitrum, Syntonix collaborate on hemophilia candidate
Biovitrum AB (metabolic and inflammation therapeutics) and Syntonix Pharmaceuticals (large molecules for blood and autoimmune conditions) have agreed to co-develop and co-commercialize Syntonix's Factor IX candidate (FIX:Fc) for hemophilia B.
- Specialty Pharmaceuticals
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.